How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) is a genetic condition causing very high LDL cholesterol and significantly increased cardiovascular risk.
• Despite available lipid-lowering therapies, less than 20% of FH patients achieve recommended LDL cholesterol targets.
• PCSK9 inhibitors are highly effective in lowering LDL cholesterol and reducing cardiovascular events, but their use is often restricted by current guidelines.

Purpose of the Study:

• To evaluate the proportion of Familial hypercholesterolemia patients who meet European guidelines criteria for PCSK9 inhibitor therapy.
• To assess the current treatment intensity and LDL cholesterol control in a large cohort of FH patients.

Main Methods:

• Analysis of 2685 Familial hypercholesterolemia patients from the Dyslipidemia Registry of the Spanish Arteriosclerosis Society.
• Patients were categorized by lipid-lowering therapy intensity and achieved LDL cholesterol levels.
• Assessment of eligibility for PCSK9 inhibition based on European Atherosclerosis Society (ESC/EAS), Spanish Arteriosclerosis Society, and European Medicines Agency recommendations.

Main Results:

• Only 17% of Familial hypercholesterolemia patients qualified for PCSK9 inhibition according to ESC/EAS guidelines, despite suboptimal LDL control in many.
• Among patients on high-intensity lipid-lowering therapy, only 23% achieved LDL below 2.6 mmol/L, and 12% of those with cardiovascular disease reached the 1.8 mmol/L target.
• A significant number of patients remained undertreated or failed to reach LDL goals even with intensive therapy.

Conclusions:

• Wider access to PCSK9 inhibitors is needed for Familial hypercholesterolemia patients with high cardiovascular risk who have difficulty achieving LDL targets.
• Current restrictive guidelines may prevent optimal management and cardiovascular event reduction in this high-risk population.